The Food and Drug Administration has issued a drug safety communication warning patients and providers about a potential increased risk of a rare eye condition in people taking GLP-1 medications, Women's Health reports.

The condition is non-arteritic anterior ischemic optic neuropathy, or NAION, which the agency describes as causing acute, painless decreased vision in one eye, including permanent vision loss. The FDA will require all GLP-1 manufacturers to add the risk to the Warnings and Precautions section of their labels, and it notes that cases have been reported for all currently marketed GLP-1 receptor agonist products.

How rare is rare

The number that matters here is 6.4 events per 100,000 per year among patients using the medications, drawn from the FDA's own meta-analysis. The agency also cited a 2024 study in JAMA Ophthalmology and a retrospective cohort study of its own.

That denominator is the part most coverage of this story will drop, and dropping it is how a label update turns into a scare. With up to 11 percent of Americans currently taking a GLP-1 for weight loss, a rare event still touches real people, which is presumably why the agency acted.

Link is not cause

Joseph Rizzo, MD, director of the Neuro-Ophthalmology Service at Mass Eye and Ear, told Women's Health there is no evidence these drugs cause NAION, only that there is a link. He frames the notice as probabilistic: the FDA has reason to believe, at least for now, that the probability of NAION is higher in patients taking these drugs.

That distinction is doing a lot of work, and it is worth keeping intact. A Warnings and Precautions entry is a flag for clinicians, not a finding of causation.

Why warn at all

Bavand Youssefzadeh, DO, an ophthalmologist at Cedars-Sinai, said severity matters alongside frequency, and that even a rare risk deserves attention when it can permanently affect vision. He also pointed out that patients prescribed these drugs, people with diabetes, high blood pressure or sleep apnea, already carry a higher baseline risk of NAION.

Mir Ali, MD, of MemorialCare Surgical Weight Loss Center, said reporting adverse effects is a duty, and called the risk not a reason to avoid the medications.

Bottom line

The FDA has moved from rumblings to a label change, which is a meaningful step, but the agency has not said these drugs cause the condition. Rizzo said the risk-to-benefit call belongs to the patient, with physicians supplying enough information to make it.